Phibro Animal Health Corp Class A PAHC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PAHC is a good fit for your portfolio.
News
-
Phibro Animal Health Corporation to Participate in Barclays Global Healthcare Conference
-
Phibro Animal Health Corporation to Participate in Bank of America 2024 Animal Health Summit
-
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
-
Phibro Animal Health Corporation Declares Quarterly Dividend
-
Phibro Animal Health Corporation Announces Chief Financial Officer Changes
Trading Information
- Previous Close Price
- $12.99
- Day Range
- $12.67–13.05
- 52-Week Range
- $9.40–15.98
- Bid/Ask
- $12.34 / $13.87
- Market Cap
- $521.28 Mil
- Volume/Avg
- 99,784 / 147,747
Key Statistics
- Price/Earnings (Normalized)
- 11.60
- Price/Sales
- 0.55
- Dividend Yield (Trailing)
- 3.72%
- Dividend Yield (Forward)
- 3.72%
- Total Yield
- 3.70%
Company Profile
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,920
- Website
- https://www.pahc.com
Comparables
Valuation
|
Metric
|
PAHC
|
ELAN
|
PETQ
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.60 | 15.34 | 13.52 |
Price/Book Value | 1.98 | 1.08 | 2.14 |
Price/Sales | 0.55 | 1.52 | 0.43 |
Price/Cash Flow | 10.10 | 11.76 | 7.48 |
Price/Earnings
PAHC
ELAN
PETQ
Financial Strength
|
Metric
|
PAHC
|
ELAN
|
PETQ
|
|---|---|---|---|
Quick Ratio | 1.30 | 1.10 | 1.37 |
Current Ratio | 3.12 | 2.75 | 2.27 |
Interest Coverage | 2.16 | −3.31 | 1.07 |
Quick Ratio
PAHC
ELAN
PETQ
Profitability
|
Metric
|
PAHC
|
ELAN
|
PETQ
|
|---|---|---|---|
Return on Assets (Normalized) | 1.29% | 2.90% | 4.26% |
Return on Equity (Normalized) | 4.56% | 6.35% | 16.31% |
Return on Invested Capital (Normalized) | 3.19% | 5.13% | 9.21% |
Return on Assets
PAHC
ELAN
PETQ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Wdrmssgk | Dzqnmv | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Bmzxcwbttt | Zhx | $69.4 Bil | |
HLN
| Haleon PLC ADR | Jcfkbnyht | Mqsb | $36.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Fsbmwyyf | Mkcy | $14.9 Bil | |
VTRS
| Viatris Inc | Hyxdbhjf | Bzw | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mlptfnt | Zcwm | $12.1 Bil | |
CTLT
| Catalent Inc | Msydjqy | Yjtwfk | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Nlkslzsd | Kztqm | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Vgwxcly | Twz | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Czwkxksdr | Mdyvl | $3.4 Bil |